- 4DMT to Participate in Upcoming Investor Conference
- 4DMT Announces Presentations at ARVO 2024 Annual Meeting
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
- 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
- 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
More ▼
Key statistics
On Tuesday, 4D Molecular Therapeutics Inc (FDMT:NSQ) closed at 26.80, -26.07% below its 52-week high of 36.25, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.79 |
---|---|
High | 27.09 |
Low | 26.26 |
Bid | 26.25 |
Offer | 27.45 |
Previous close | 26.76 |
Average volume | 392.00k |
---|---|
Shares outstanding | 51.16m |
Free float | 49.35m |
P/E (TTM) | -- |
Market cap | 1.37bn USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼